These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37351169)

  • 1. DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy
    Reuvers TGA; Verkaik NS; Stuurman D; de Ridder C; Groningen MCC; de Blois E; Nonnekens J
    Theranostics; 2023; 13(10):3117-3130. PubMed ID: 37351169
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.
    Nonnekens J; van Kranenburg M; Beerens CE; Suker M; Doukas M; van Eijck CH; de Jong M; van Gent DC
    Theranostics; 2016; 6(11):1821-32. PubMed ID: 27570553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.
    Evans JS; Beaumont J; Braga M; Masrour N; Mauri F; Beckley A; Butt S; Karali CS; Cawthorne C; Archibald S; Aboagye EO; Sharma R
    Eur J Cancer; 2022 Nov; 176():110-120. PubMed ID: 36208569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing the anti-tumour activity of
    Cullinane C; Waldeck K; Kirby L; Rogers BE; Eu P; Tothill RW; Hicks RJ
    Sci Rep; 2020 Jun; 10(1):10196. PubMed ID: 32576907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to
    Waldeck K; Van Zuylekom J; Cullinane C; Gulati T; Simpson KJ; Tothill RW; Blyth B; Hicks RJ
    Theranostics; 2023; 13(14):4745-4761. PubMed ID: 37771787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.
    Duan H; Ferri V; Fisher GA; Shaheen S; Davidzon GA; Iagaru A; Mari Aparici C
    Oncologist; 2022 Jun; 27(6):447-452. PubMed ID: 35641196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro.
    Jin XF; Auernhammer CJ; Ilhan H; Lindner S; Nölting S; Maurer J; Spöttl G; Orth M
    J Nucl Med; 2019 Sep; 60(9):1240-1246. PubMed ID: 30796167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair.
    Gustafsson AS; Abramenkovs A; Stenerlöw B
    Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model.
    Sharma R; Earla B; Baidoo KE; Zeiger MA; Madigan JP; Escorcia FE; Sadowski SM
    Mol Cancer Ther; 2023 Sep; 22(9):1052-1062. PubMed ID: 37487000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair kinetics in SCID mice Sertoli cells and DNA-PKcs-deficient mouse embryonic fibroblasts.
    Ahmed EA; Vélaz E; Rosemann M; Gilbertz KP; Scherthan H
    Chromosoma; 2017 Mar; 126(2):287-298. PubMed ID: 27136939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal Imaging of 2-Cycle PRRT with
    Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
    J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.
    Toulany M; Kehlbach R; Florczak U; Sak A; Wang S; Chen J; Lobrich M; Rodemann HP
    Mol Cancer Ther; 2008 Jul; 7(7):1772-81. PubMed ID: 18644989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.
    Briest F; Koziolek EJ; Albrecht J; Schmidt F; Bernsen MR; Haeck J; Kühl AA; Sedding D; Hartung T; Exner S; Welzel M; Fischer C; Grötzinger C; Brenner W; Baum RP; Grabowski P
    Neoplasia; 2021 Jan; 23(1):80-98. PubMed ID: 33246310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
    Adant S; Shah GM; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):907-921. PubMed ID: 31492995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of
    Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence.
    Liu Y; Efimova EV; Ramamurthy A; Kron SJ
    J Cell Sci; 2019 Jul; 132(13):. PubMed ID: 31189537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [
    Klomp MJ; Dalm SU; van Koetsveld PM; Dogan F; de Jong M; Hofland LJ
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK.
    Murphy R; Chander G; Martinez M; Ward C; Khan SR; Naik M; Barwick T; Aboagye E; Sharma R
    BMJ Open; 2023 Oct; 13(10):e075221. PubMed ID: 37879695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
    Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
    Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.